Blood Cancers Today Staff Writers

Staff Writers

Articles by Blood Cancers Today Staff Writers

Blood Cancers Today Staff WritersMyeloma | September 21, 2023
The phase III study included patients who received at least one prior line of therapy.
Read More
Blood Cancers Today Staff WritersMyeloma | September 21, 2023
The researchers sought to assess the utility of MRD outside the context of clinical trials.
Blood Cancers Today Staff WritersMyeloma | September 21, 2023
Daratumumab in combination with lenalidomide and dexamethasone provided greater OS in most subgroups.
Blood Cancers Today Staff WritersMantle Cell Lymphoma | September 9, 2023
Brexucabtagene autoleucel is a promising therapy in relapsed or refractory MCL.
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | September 9, 2023
A research team sought in their study to determine if the IPSS-M could also apply to CMML.
Blood Cancers Today Staff WritersMantle Cell Lymphoma | September 8, 2023
Pirtobrutinib can be safely used along with concomitant antithrombotic therapy (CAT) in treating B-cell malignancies.
Blood Cancers Today Staff WritersMantle Cell Lymphoma | September 8, 2023
The overall response rate was 83.8% and the CR rate was 73% after the median follow-up of eight months.
Blood Cancers Today Staff WritersMantle Cell Lymphoma | September 8, 2023
A first-line induction regimen that alternates VR-CAP with R-DHAP can improve treatment response in newly diagnosed MCL.
Blood Cancers Today Staff WritersMeeting News | September 6, 2023
Allogeneic HSCT can yield favorable outcomes in treating patients with therapy-related MDS.
Blood Cancers Today Staff WritersMeeting News | September 5, 2023
A presentation by Dr. Rami Komrokji at the Eleventh SOHO Annual Meeting gave additional insights into the COMMANDS trial.
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | September 5, 2023
Luspatercept is highly effective in treating ESA-naïve patients with LR-MDS.
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | September 1, 2023
Response rates were high, and OS was improved in patients receiving venetoclax, although not statistically significant.
Blood Cancers Today Staff WritersHodgkin Lymphoma | August 28, 2023
Single-cell analysis has shed new light on the unique biology of classic Hodgkin lymphoma (HL).
Blood Cancers Today Staff WritersMyeloma | June 8, 2023
Researchers are evaluating the combination to establish a recommended phase III dose for the first-line setting.
Blood Cancers Today Staff WritersMyeloma | June 7, 2023
In the trial, patients received talquetamab at 0.4 mg/kg weekly or 0.8 mg/kg every two weeks.
Blood Cancers Today Staff WritersAggressive B-Cell Lymphoma | June 5, 2023
CAR T-cell therapy with lisocabtagene maraleucel resulted in survival benefits for patients with relapsed or refractory.
Blood Cancers Today Staff WritersAcute Lymphoblastic Leukemia | June 5, 2023
Older adult patients with newly diagnosed Ph- ALL may benefit from this combination therapy.
Blood Cancers Today Staff WritersMyeloma | June 5, 2023
Patients treated with the higher dose had higher overall response rates.
Blood Cancers Today Staff WritersMyeloma | June 5, 2023
Approximately one-third of the heavily pretreated patients in the small study responded to therapy.
Blood Cancers Today Staff WritersMyeloma | June 4, 2023
The overall response rate was 87.8% with 73% of patients achieving complete response.